Common questions about NexGard (FAQ)
Q: What is the main reason NexGard is prescribed?
A: Regulatory documents describe NexGard's use in the treatment of flea infestations and the treatment and control of tick infestations in dogs. It is also described as being used as part of a strategy to manage Flea Allergy Dermatitis (FAD). Additionally, the medicine is indicated for the treatment of demodicosis and sarcoptic mange, which are skin conditions caused by mites.
Q: Is NexGard the same as other medicines for the same condition?
A: Official documentation clarifies that NexGard's active ingredient, afoxolaner, is a member of the isoxazoline class of antiparasitic agents. It is unique in its pharmaceutical form as a beef-flavored soft chewable tablet, which is a key descriptive difference from other products that are administered topically to the skin.
Q: Can NexGard be used for long-term treatment?
A: The regulatory schedule is designed for monthly administration. Official product information describes that continuous, monthly treatment is recommended in areas where the external parasites are present all year.
Q: Does NexGard treat symptoms, or does it address the underlying issue?
A: The product's stated purpose is to treat the underlying issue of infestation. Studies indicate that the active ingredient kills the fleas and ticks that feed on the host, thereby addressing the root cause of associated symptoms like skin irritation rather than just treating the visible symptoms alone.
Q: What is the typical time frame to see the expected effects of NexGard?
A: Official studies on the speed of action indicate that flea mortality begins within 4 hours of administration and reaches a specified level by 8 hours. Ticks are typically killed within 48 hours of attachment to the dog.
Q: Is NexGard considered a high-risk medication by regulatory bodies?
A: Regulatory agencies require a precaution to be listed due to the isoxazoline class of compounds being associated with neurological adverse reactions, such as seizures and tremors. Regulatory approval defines the conditions under which the product's risk profile is deemed acceptable for its stated indications.
Q: What is known about the long-term safety profile of NexGard?
A: Clinical field studies have supported the required monthly administration schedule. During these initial studies, common adverse reactions such as vomiting and diarrhea were generally described as self-limiting, which means they were of short duration and resolved without further action.
Q: Are there different strengths of NexGard available?
A: Yes, the official product information confirms that NexGard is available in multiple strengths of chewable tablets. These different strengths are available to facilitate the weight-dependent dosing protocol outlined in the product information.
Q: What is the significance of the box warning (or black box warning) on NexGard's label?
A: The US FDA requires a cautionary statement regarding the isoxazoline class, which includes afoxolaner. This warning highlights that the class of compounds has been associated with neurological adverse reactions, such as seizures and tremors. Official labeling states that caution is required in dogs with a history of seizure disorders.
Q: What is the mechanism by which NexGard is absorbed by the body?
A: After the chewable is consumed, official data states that the active ingredient, afoxolaner, is rapidly absorbed into the dog's bloodstream (systemic circulation). It has a high level of bioavailability, which allows the product to be distributed throughout the body where it can then be ingested by feeding parasites.
Q: Where can I find the full list of ingredients in NexGard?
A: The main active ingredient is Afoxolaner. The complete list of all ingredients, including excipients (inactive substances that help formulate the chewable), is detailed in the official regulatory documents, such as the FDA Prescribing Information and the European Summary of Product Characteristics.
Q: Can NexGard affect mood or sleep?
A: The official safety data lists rare neurological signs, such as seizures and tremors, as possible adverse reactions. However, the regulatory safety profile does not explicitly document any specific effects on a dog's mood or sleeping patterns.
Q: Does taking NexGard affect laboratory test results?
A: Safety studies in the target species indicated that the administration of the medicine did not result in clinically significant changes to standard blood tests, such as hematology or clinical chemistry results. The official product information does not document interference with all general laboratory test results.
Q: What does regulatory approval mean for NexGard's use?
A: Regulatory approval, such as a Marketing Authorization from the FDA or EMA, signifies that the health authority has determined that the product's benefits are judged to outweigh its known risks for its specific, stated purposes. This approval defines the drug's official indications and the necessary instructions for its use.
Q: How quickly is NexGard eliminated from the body?
A: Official pharmacokinetic studies show that the active ingredient, afoxolaner, has a long terminal half-life in the dog's blood plasma. This pharmacokinetic characteristic is the underlying reason the product is approved for a single dose once every month.
Q: Is there a cumulative effect with long-term use of NexGard?
A: Pharmacokinetic studies conducted after repeated monthly administration indicated that the active ingredient achieves a steady state in the bloodstream. The official data suggests that afoxolaner accumulates by less than four-fold, supporting the consistency of the approved monthly dosing regimen.
Q: What kind of research has been done on NexGard?
A: Official research supporting the product's authorization has involved controlled laboratory and field studies. These studies primarily focused on demonstrating the medicine's efficacy against various species of fleas and ticks, determining its speed of kill, and confirming its safety when used in healthy dogs and alongside other commonly prescribed veterinary medicines.
Q: Is it possible for NexGard to interact with common over-the-counter supplements?
A: Official documentation indicates that no known interactions with other medicinal products are currently documented. Safety has been confirmed when administered alongside several common classes of therapeutic agents. Therefore, no mandatory rules are required to separate the timing of this medicine from other products.
Q: How does the way NexGard works compare to older treatments?
A: The way NexGard works is due to its active ingredient, afoxolaner, belonging to the isoxazoline chemical class. This compound acts by blocking GABA-Cl^- channels, which are chloride ion channels in the nervous system of the parasites. This mechanism of action is described in official documents as being distinct from older classes of anti-parasitic agents.
Q: Are there special warnings about NexGard for older adults?
A: Official regulatory documents highlight the importance of using caution in dogs with a history of neurological disorders, such as seizures. However, the labels and prescribing information do not contain any specific restrictions or warnings that are based only on the dog's age.
Q: What did the main clinical trials of NexGard focus on?
A: The main clinical trials focused on establishing the medicine's efficacy and the duration of its protection against flea and tick infestations. These studies also provided the essential safety data that supports the required once-monthly administration in the approved target species.
Q: Why do official documents mention potential for drug interactions with NexGard?
A: Official regulatory documents state that there are no known interactions documented with other medicinal products. Studies conducted where the medicine was administered alongside common drug classes demonstrated no adverse reactions, confirming a low concern for drug-drug interactions.
Q: What does the term 'contraindicated' mean in relation to NexGard?
A: The term 'contraindicated' means the medicine should not be used in specific situations due to the risk outweighing the benefit. Official labeling states that NexGard is absolutely contraindicated for dogs with a known hypersensitivity (an allergic reaction) to the active ingredient, afoxolaner, or to any of the other excipients (inactive ingredients) in the chewable tablet.
Q: Can NexGard be crushed or split to make it easier to swallow?
A: Regulatory documents describe that the full, entire soft chewable tablet is required to be consumed. This instruction is in place to ensure that the complete and correct therapeutic amount of the active ingredient is received by the dog.
Q: Are the side effects of NexGard temporary, or can they be permanent?
A: The most commonly reported adverse reactions, such as vomiting and diarrhea, are generally described in official documents as being temporary and of short duration. The documents do not explicitly state whether the very rare neurological signs, such as seizures, are permanent.
Q: What is the research background for the use of NexGard in treating a specific condition?
A: The research background establishes the official uses of NexGard in the treatment of flea infestations, tick infestations, demodicosis, and sarcoptic mange. These studies demonstrated the product’s efficacy and the sustained duration of its action against these specific external parasites.
